Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Designer drugs: pipe-dreams or realities?

W E Gutteridge1

  • 1WHO/TDR/TDP, Geneva, Switzerland.

Parasitology
|January 1, 1997
PubMed
Summary

Developing new chemotherapies for parasitic and tropical diseases requires significant upfront investment in rational molecular design. This approach, though resource-intensive, is justified by the high cost of chemical synthesis and the need for validated drug targets.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TDR collaboration with the pharmaceutical industry.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2006
Same author

New tools for malaria therapy.

Parassitologia·2000
Same author

Nitric oxide synthase activity in malaria-infected mice.

Parasite immunology·1996
Same author

Characterization of the enhanced transport of L- and D-lactate into human red blood cells infected with Plasmodium falciparum suggests the presence of a novel saturable lactate proton cotransporter.

The Journal of biological chemistry·1995
Same author

Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro.

Experimental parasitology·1995
Same author

The activity of hydroxynaphthoquinones against Leishmania donovani.

The Journal of antimicrobial chemotherapy·1992

Area of Science:

  • Drug Discovery and Development
  • Parasitology
  • Tropical Medicine

Background:

  • Urgent need for novel chemotherapies against parasitic infections in animals and human tropical diseases.
  • Current drug discovery methods are resource-intensive, necessitating efficient approaches.

Purpose of the Study:

  • To advocate for and justify the application of rational molecular design in discovering new chemotherapies.
  • To address the challenges and potential of rational drug design versus empirical synthesis.

Main Methods:

  • Discussion of rational molecular design principles and their application.
  • Comparison of rational design with empirical synthesis, including combinatorial approaches.
  • Emphasis on target validation as a critical step.

Main Results:

  • Rational molecular design requires substantial upfront investment but is justifiable.
  • While not all aspects are fully rational, the approach is viable where possible.
  • It is premature to definitively compare the cost-effectiveness of rational design versus empirical synthesis.

Conclusions:

  • Continued validation of drug targets is essential for advancing rational design.
  • Both rational design and empirical synthesis may coexist and evolve in parallel.
  • Discovery research should not be halted due to development concerns; collaborative models are encouraged.

Related Experiment Videos